Company Interview / Orthocell's nerve test in Asia

Key takeaways:

First commercial sales in Hong Kong seen as strategic gateway to Greater ChinaFocus on building clinical track record and expanding regional partnershipsEuropean regulatory approvals targeted alongside growth in US and AsiaStrong cash position with no debt supports global expansion plans

Orthocell (ASX: OCC) has marked a significant achievement with the inaugural commercial sales of its nerve repair treatment in Hong Kong. Paul Anderson highlights Hong Kong’s strategic value, noting its role as a gateway to the broader Guangdong-Hong Kong-Macao Greater Bay Area, connecting Hong Kong, Macao, and Guangdong and offering access to a population exceeding 100 million. Anderson points to the sophistication of the Hong Kong market and established surgical and research networks as crucial to Orthocell’s regional expansion plans.

Anderson outlines that the path into the wider Chinese market centres on building a solid track record in Hong Kong, where scientific officer Professor Minghao Zheng is leading training with both distributors and surgeons. Interest from clinicians is described as strong, with ongoing education and onboarding for prospective clients bolstering confidence in Orthocell’s offering. Alongside existing markets in Singapore and the United States, Orthocell is also preparing for regulatory submissions in the European Union, the world’s second largest healthcare market.

Turning to financials, Anderson states Orthocell carries no debt and holds $50 million in cash following a recent $30 million capital raise with Canaccord. With over 3,000 procedures conducted annually in Australia, Orthocell anticipates robust revenue growth, particularly as US distribution broadens with more than 20 distributors now engaged